It is predicted that expressing TNF locally from an oncotropic virus such as MYXV, which can only productively propagate in tumor cells, and thus limit the induced level of circulating TNF, will lower the risk associated with systemic TNF treatment while hopefully preserving its anti-cancer properties. This evidence concerns the gene TNF and cancer.